Cavinton Comfort, 10 mg 90 pcs

An agent which improves cerebral blood circulation and cerebral metabolism. It inhibits phosphodiesterase activity, which promotes accumulation of CAMP in tissues. It has a vasodilatory effect mainly on cerebral vessels, which is due to direct myotropic spasmolytic action.

The systemic BP decreases slightly. It improves blood supply and microcirculation in the brain tissue, decreases platelet aggregation and normalizes the rheological blood properties.

It improves the tolerance of hypoxia by brain cells by promoting oxygen transport to the tissues by reducing the affinity of red blood cells, increasing the absorption and metabolism of glucose. Increases the content of catecholamines in brain tissues.

Pharmacokinetics

In oral administration, it is rapidly absorbed from the gastrointestinal tract. C_max in plasma is reached after approximately 1 h. When parenteral administration, V_d is 5.3 l/kg. T_1/2 is about 5 h.

Indications

Cerebral circulation disorders (including stroke, vertebrobasilar insufficiency, brain injury, atherosclerotic changes in cerebral vessels, vascular dementia, hypertensive and post-traumatic encephalopathy), intermittent insufficiency and spasm of cerebral vessels;

partial occlusion of arteries, headache, dizziness (including labyrinthine origin), memory impairment, movement disorders, incl. apraxia, aphasia, arteriolosclerotic and angiospastic changes in the retina and choroid, arterial and venous thrombosis of the vessels of the eye, degenerative changes in the macula, secondary glaucoma due to vascular obstruction;

age-related, vascular or toxic (drug-induced) hearing impairment, Meniere’s disease, cochleovestibular neuritis, tinnitus;

vasovegetative manifestations of menopausal syndrome (in combination with hormone therapy).

Pharmacological effect

A drug that improves cerebral circulation and cerebral metabolism. Inhibits the activity of phosphodiesterase, which promotes the accumulation of cAMP in tissues. It has a vasodilating effect mainly on the vessels of the brain, which is due to a direct myotropic antispasmodic effect.

Systemic blood pressure decreases slightly. Improves blood supply and microcirculation in brain tissue, reduces platelet aggregation, and helps normalize the rheological properties of blood.

Improves the tolerance of hypoxia by brain cells, promoting the transport of oxygen to tissues due to a decrease in the affinity of red blood cells for it, increasing the absorption and metabolism of glucose. Increases the content of catecholamines in brain tissue.

Pharmacokinetics

When taken orally, it is quickly absorbed from the gastrointestinal tract. Cmax in blood plasma is reached after approximately 1 hour. With parenteral administration, Vd is 5.3 l/kg. T1/2 is about 5 hours.

Special instructions

It is not recommended to prescribe for labile blood pressure and low vascular tone.

Prescribe with caution to patients taking antihypertensive drugs or drugs that increase the QT interval, as well as patients with poor tolerance to Vinca minor alkaloids and those suffering from liver failure.

S/C, IM and IV injection are not allowed.

Should not be used during work by vehicle drivers and people whose profession involves increased concentration of attention.

When administered parenterally to patients with diabetes, monitoring of blood glucose levels is necessary (the solution contains sorbitol). In the presence of long QT interval syndrome or with the simultaneous use of drugs that provoke prolongation of the QT interval, ECG monitoring is necessary.

In case of hemorrhagic stroke, parenteral use of the drug is permissible only after the disappearance of acute symptoms (after 5–7 days).

There are not enough observations on the use of the drug in pediatric practice.

Active ingredient

Vinpocetine

Composition

1 tablet contains

Active ingredient:

vinpocetine – 10 mg.

Excipients:

mannitol – 75.6 mg,

pregelatinized corn starch – 38 mg,

butyl methacrylate copolymer – 9 mg,

low-substituted hyprolose – 8 mg,

crospovidone – 8 mg,

magnesium stearate – 2.85 mg,

sodium stearyl fumarate – 2.8 mg,

colloidal silicon dioxide – 1.6 mg,

aspartame – 1.28 mg,

stearic acid – 1.26 mg,

sodium lauryl sulfate – 0.9 mg,

dimethicone – 0.39 mg,

orange flavor – 0.32 mg.

Contraindications

Hypersensitivity, severe forms of ischemic heart disease and arrhythmias, the first days after cerebral hemorrhagic stroke, increased intracranial pressure; pregnancy, breastfeeding.

Side Effects

From the nervous system and sensory organs: dizziness, headache, insomnia, drowsiness, weakness.

From the cardiovascular system and blood (hematopoiesis, hemostasis): slowing of intraventricular conduction; ST segment depression and QT interval prolongation, hypotension, tachycardia, extrasystole, skin redness, thrombophlebitis at the injection site.

From the gastrointestinal tract: dry mouth, nausea, heartburn.

From the skin: sweating.

Other: allergic reactions.

Interaction

When used concomitantly with warfarin, a slight decrease in the anticoagulant effect of warfarin has been reported.

With simultaneous parenteral use of vinpocetine and heparin, the risk of bleeding may increase.

Storage conditions

In a place protected from light, at a temperature of 15–30 °C.

Manufacturer

Gedeon Richter-RUS, Russia